Heather Huet

611 total citations
13 papers, 264 citations indexed

About

Heather Huet is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Heather Huet has authored 13 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Heather Huet's work include Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (5 papers) and Immunotherapy and Immune Responses (4 papers). Heather Huet is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (5 papers) and Immunotherapy and Immune Responses (4 papers). Heather Huet collaborates with scholars based in United States, Switzerland and Belgium. Heather Huet's co-authors include Sanela Bilic, Drew Rasco, Kyriakos P. Papadopoulos, Randi Isaacs, Amit Mahipal, Matthias Hofmann, Ravi Salgia, Aliya N. Husain, Soundararajan Krishnaswamy and Reshmi Parameswaran and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Heather Huet

13 papers receiving 258 citations

Peers

Countries citing papers authored by Heather Huet

Since Specialization

Citations

This map shows the geographic impact of Heather Huet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather Huet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather Huet more than expected).

Fields of papers citing papers by Heather Huet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather Huet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather Huet. The network helps show where Heather Huet may publish in the future.

Co-authorship network of co-authors of Heather Huet

This figure shows the co-authorship network connecting the top 25 collaborators of Heather Huet. A scholar is included among the top collaborators of Heather Huet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather Huet. Heather Huet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression 2019 ·Cancer Immunology Research ·Ali Roghanian, Guangan Hu, Christophe Fraser, Maneesh Singh, Russell B. Foxall, Matthew J. Meyer, Emma Lees, Heather Huet, Martin J. Glennie, Stephen A. Beers, Sean H. Lim, Margaret Ashton‐Key, Stephen M. Thirdborough, Mark S. Cragg, Jianzhu Chen	29
2	Abstract B105: ACTR707: a novel T-cell therapy for the treatment of relapsed or refractory CD20+ B cell lymphoma in combination with rituximab 2018 ·Molecular Cancer Therapeutics ·Greg Motz, Kathleen R. Whiteman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ann Ranger, Heather Huet, Kathleen E. McGinness, Birgit C. Schultes, (unknown), Michael J. Vasconcelles, Seth A. Ettenberg	3
3	ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab 2017 ·Blood ·Luke P. Akard, Samantha Jaglowski, Steven M. Devine, Matthew McKinney, Michael J. Vasconcelles, Heather Huet, Seth A. Ettenberg, Ann Ranger, Jeremy S. Abramson	3
4	Abstract 4605: Efficient targeting of BCMA-positive multiple myeloma cells by antibody-coupled T-cell receptor (ACTR) engineered autologous T cells in combination with an anti-BCMA antibody 2017 ·Cancer Research ·Tooba A. Cheema, (unknown), Katie O’Callaghan, Lori Westendorf, Luke S. Manlove, Shyra J. Gardai, Allison Nelson, (unknown), Kathleen E. McGinness, Birgit C. Schultes, Seth A. Ettenberg, Django Sussman, Heather Huet	1
5	Targeting CD20+ Relapsed Refractory B Cell Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR) Engineered Autologous T Cells, in Combination with Rituximab 2016 ·Blood ·Heather Huet, (unknown), R. Anthony Barnitz, (unknown), Kathleen E. McGinness, (unknown), Tooba A. Cheema, Kathleen R. Whiteman, Birgit C. Schultes, Ann Ranger, Lan Cao, (unknown), Michael J. Vasconcelles, Seth A. Ettenberg	2
6	Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor 2015 ·Cancer Chemotherapy and Pharmacology ·Kyriakos P. Papadopoulos, Randi Isaacs, Sanela Bilic, (unknown), Heather Huet, Matthias Hofmann, Drew Rasco, (unknown), (unknown), (unknown), Amit Mahipal	124
7	Effector-Mediated Eradication of Precursor B Acute Lymphoblastic Leukemia with a Novel Fc-Engineered Monoclonal Antibody Targeting the BAFF-R 2014 ·Molecular Cancer Therapeutics ·Reshmi Parameswaran, (unknown), Fei Fei, Hisham Abdel‐Azim, Anna Arutyunyan, (unknown), Margaret E. McLaughlin, Hermann Gram, Heather Huet, John Groffen, Nora Heisterkamp	32
8	B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo 2013 ·Blood ·Emily M. McWilliams, Carolyn Cheney, Jeffrey A. Jones, Joseph M. Flynn, Kami J. Maddocks, Leslie A. Andritsos, Heather Huet, Hermann Gram, Johan Baeck, Natarajan Muthusamy, John C. Byrd	2
9	Differential expression of RON in small and non–small cell lung cancers 2012 ·Genes Chromosomes and Cancer ·Rajani Kanteti, Soundararajan Krishnaswamy, Daniel V.T. Catenacci, Yi‐Hung Carol Tan, Essam El‐Hashani, Gustavo M. Cervantes, Aliya N. Husain, Maria Tretiakova, Everett E. Vokes, Heather Huet, Ravi Salgia	32
10	Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches 2012 ·Cancer Research ·Heather Huet, Alwin G. Schuller, Jing Li, Jennifer Johnson, Bruno Dombrecht, Kris Meerschaert, Karen Cromie, Sanela Bilic, Sharon Li, Andrew P. Garner, (unknown), Rajiv Chopra, Kirk Clark, (unknown), Stephen E. Fawell, David R. Stover, William R. Sellers, Seth A. Ettenberg	7
11	Antibodies directed to α6β4 highlight the adhesive and signaling functions of the integrin in breast cancer cell lines 2010 ·Cancer Biology & Therapy ·(unknown), Samuel K. Cho, (unknown), Yan Ren, Ling Ling Chen, Anne E. Cheung, (unknown), Rachel Rennard, (unknown), Christilyn Graff, Beth Browning, Heather Huet, Karen R. McLachlan	5
12	Integrin-Blocking Antibodies Delay Keratinocyte Re-Epithelialization in a Human Three-Dimensional Wound Healing Model 2010 ·PLoS ONE ·Christophe Egles, Heather Huet, (unknown), Sam Cho, Shumin Dong, Avi Smith, (unknown), Karen R. McLachlan, Jonathan A. Garlick	20
13	Functional Characterization of Integrin α6β4 Adhesion Interactions Using Soluble Integrin Constructs Reveals the Involvement of Different Functional Domains in the β4 Subunit 2008 ·Cell Communication & Adhesion ·Ling Ling Chen, (unknown), Samuel K. Cho, Beth Browning, (unknown), Heather Huet, Anne E. Cheung, (unknown), (unknown), Michael J. Shields, R. Blake Pepinsky, Karen R. McLachlan	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact